The present invention relates to a nanobody or an antigen-binding fragment thereof that specifically binds to HER3, a composition containing the nanobody or the antigen-binding fragment thereof, and a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof. In addition, the present invention also relates to the use of the nanobody or the antigen-binding fragment thereof in the treatment and diagnosis of diseases.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A nanobody specifically binding to HER2 or an antigen-binding fragment thereof, a composition comprising the nanobody or the antigen-binding fragment thereof, and a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof. In addition, the present invention further relates to the use of the nanobody or the antigen-binding fragment thereof in the treatment and diagnosis of diseases.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present application relates to an antigen-binding protein and use thereof, and specifically relates to an antigen-binding protein capable of inhibiting competitive binding of IGF-IR to ligands thereof with an IC50 value of about 1.0 μg/mL or less in a competitive ELISA.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A nanobody specifically binding to c-MET or an antigen-binding fragment thereof, a composition containing the nanobody or the antigen-binding fragment thereof, and a nucleic acid molecule encoding the nanobody or the antigen-binding fragment thereof. Also provided is a use of the nanobody or the antigen-binding fragment thereof in the treatment and diagnosis of diseases.
A single-domain antibody specifically binding to CDCP1 or an antigen-binding fragment thereof, a polypeptide construct and a conjugate containing the single-domain antibody or the antigen-binding fragment thereof, a nucleic acid molecule encoding the single-domain antibody or the antigen-binding fragment thereof and a host cell containing same, and a related use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present application relates to an anti-tumor compound and use thereof, specifically, the present application relates to a ligand conjugate or a tautomer, a mesomer, a racemate, an enantiomer and a diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. The present application further relates to a method for preparing the ligand conjugate and the use thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
An antigen binding protein and the use thereof. The antigen binding protein can compete with pembrolizumab for binding to the same or overlapping PD-1 epitope. The antigen binding protein can effectively inhibit the binding of human PD-L1 to human PD-1 with an EC50 of approximately 2 μg/mL or less.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A ligand conjugate, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or pharmaceutically acceptable salt or hydrate thereof; same comprises a structure as represented by formula I and mayb be used as an anti-tumor drug.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a prodrug compound, a preparation method, and the use thereof. In particular, the present invention provides a compound as represented by formula (I), a preparation method, and the use thereof as a prodrug for preparing topical formulations.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
10.
TOXIN MOLECULE SUITABLE FOR ANTIBODY-DRUG CONJUGATE
The present invention provides a toxin molecule suitable for an antibody drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. The compound of the present invention can be used in the preparation of a pharmaceutical composition for treating diseases associated with tumor cell proliferation.
The present invention provides a toxin molecule suitable for an antibody drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. The compound of the present invention can be used in the preparation of a pharmaceutical composition for treating diseases associated with tumor cell proliferation.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a prodrug in the preparation of an external preparation.
C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A toxin molecule suitable for an antibody-drug conjugate is provided. Specifically, a compound represented by the following formula (I), or a pharmaceutically acceptable salt or hydrate thereof is provided. The compound can be used to prepare a pharmaceutical composition used for treating diseases associated with tumor cell proliferation.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
The present invention relates to a multispecific antibody targeting a programmed cell death receptor-1 (PD-1) and a vascular endothelial growth factor (VEGF), a pharmaceutical composition comprising the multispecific antibody, a nucleic acid molecule and a vector encoding the multispecific antibody, a host cell, and the use thereof for treating tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Provided are an anti-B7-H3 antibody and preparation thereof and a use thereof. Further provided is a drug conjugate and recombinant protein containing the antibody. The antibody of the present invention can be effectively endocytosed by cells, and an antibody-conjugated drug prepared by using the antibody of the present invention shows a tumor inhibition effect.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The present invention provides a JAK kinase inhibitor and a preparation and application thereof, and the present invention specifically provides a compound having a structure represented in the following formula I, an enantiomer thereof, or a pharmaceutically acceptable salt thereof. The compound has uniquely advantageous JAK kinase inhibitory activity, and as such may be used for treatment of a disease or illness related to JAK kinase activity or expression level.
The present invention provides a JAK kinase inhibitor and a preparation and application thereof, and the present invention specifically provides a compound having a structure represented in the following formula I, an enantiomer thereof, or a pharmaceutically acceptable salt thereof. The compound has uniquely advantageous JAK kinase inhibitory activity, and as such may be used for treatment of a disease or illness related to JAK kinase activity or expression level.
A nitrogen-containing heterocyclic compound, a preparation method therefor, an intermediate thereof, and an application thereof. A nitrogen-containing heterocyclic compounds as shown in formula II-a, II-b, I-c, or I-d, a preparation method therefor, an intermediate thereof, and an application thereof. The compound has strong inhibitory activity on PARP1, particularly has a significant advantage in PARP1/PARP2 selectivity over the positive controls Olaparib and AZD5305, and can effectively reduce blood toxicity caused by PARP2.
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
An antitumor compound and the use thereof. Specifically, the present invention relates to a ligand conjugate or a tautomer, a mesomer, a racemate, an enantiomer and a diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the ligand conjugate and the use thereof.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a prodrug compound, a preparation method therefor, and the use thereof. In particular, the present invention provides a compound as represented by formula (I), a preparation method therefor, and the use thereof as a prodrug for preparing an external preparation.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention provides a toxin molecule suitable for an antibody-drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. The compound of the present invention can be used in the preparation of a pharmaceutical composition for treating diseases associated with tumor cell proliferation.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
23.
Cyclic molecules as Bruton's tyrosine kinase inhibitor
The present invention relates to a novel molecule with protein tyrosine kinase inhibitory activity, and the synthesis and usage thereof. Specifically, the present invention relates to compound by formula A, pharmaceutically acceptable salts, hydrates or solvates thereof, and the synthesis and usage thereof.
Provided are an anti-B7-H3 antibody and preparation therefor and a use thereof. Further provided is a drug conjugate and recombinant protein containing the antibody. The antibody of the present invention can be effectively endocytosed by cells, and an antibody-conjugated drug prepared by using the antibody of the present invention shows a tumor inhibition effect.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a JAK kinase inhibitor and a preparation and application thereof, and the present invention specifically provides a compound having a structure represented in the following formula I, an enantiomer thereof, or a pharmaceutically acceptable salt thereof. The compound has uniquely advantageous JAK kinase inhibitory activity, and as such may be used for treatment of a disease or illness related to JAK kinase activity or expression level.
A61K 31/547 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 25/00 - Drugs for disorders of the nervous system
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 19/06 - Antigout agents, e.g. antihyperuricemic or uricosuric agents
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
26.
CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR
The present invention describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using the compound. Specifically, the present invention describes a compound of formula (A) or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and methods of synthesizing and using the compound.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
patents
